Vodafone and AstraZeneca have formed a global partnership to use mobile health (mHealth) services to improve health outcomes for patients with cardiovascular conditions.
Announcing this today, the two companies said in a statement that the collaboration would create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more effectively.
In this partnership, Vodafone will provide the technology, infrastructure and expertise for these services, as well as the ability to capture data from a variety of sources to improve overall engagement between patients and their Health Care Professionals (HCPs).
HCPs will be able to give patients the option to use these mHealth services.
The project will be led by the Intelligent Pharmaceutical Group within AstraZeneca, part of Global Medicines Development, working in close collaboration with the in-country marketing teams
"Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients," said Vodafone Director for Machine to Machine, Erik Brenneis. "AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services."
Sign up for MIS Asia eNewsletters.